Ganitumab for the treatment of small-cell lung cancer, PMID: 25189625
Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy, PMID: 24727326
Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy, PMID: 28427155
A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer, PMID: 29572245
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial, PMID: 23414585
IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice, PMID: 24492468
Epitope-specific mechanisms of IGF1R inhibition by ganitumab, PMID: 23383308
Differential Pharmacokinetics of Ganitumab in Patients With Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers, PMID: 27121941
Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models, PMID: 21385891
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors, PMID: 22510349
Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts, PMID: 23348048
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors, PMID: 22810805
Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors, PMID: 22508822
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial, PMID: 25609246
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer, PMID: 28601388
Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study, PMID: 24782485
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer, PMID: 24919569
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer, PMID: 22700995
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors, PMID: 23572164
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab, PMID: 24816908
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor, PMID: 23741071
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer, PMID: 23510984
A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells, PMID: 25344862
Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts, PMID: 23823800
Recent advances in targeted therapy for Ewing sarcoma, PMID: 27635231
Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review, PMID: 32770529
Minireview: Were the IGF Signaling Inhibitors All Bad?, PMID: 26366975
Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade, PMID: 26429980
The impact of timing of EGFR and IGF-1R inhibition for sensitizing head and neck cancer to radiation, PMID: 22843870
Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials, PMID: 28256961
Insulin-like growth factor receptor inhibitors: baby or the bathwater?, PMID: 22761272
Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts, PMID: 22562985
Flagellate Dermatitis in a Child Most Likely Secondary to Doxorubicin, PMID: 28804924
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer, PMID: 29123263
Anticancer IGF1R classes take more knocks, PMID: 23535923
IGF-1R inhibition: right direction, wrong pathway?, PMID: 23414584
Therapy: Blockade of IGF-1R-not effective in neuroendocrine tumours, PMID: 23732282
A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer, PMID: 27806321
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer, PMID: 22678353
Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers, PMID: 23051797
AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways, PMID: 21846689
Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma, PMID: 20652976
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1, PMID: 19786654
AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells, PMID: 19366899
Targeting IGF-IR improves neoadjuvant chemotherapy efficacy in breast cancers with low IGFBP7 expression., PMID:39362991
Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma., PMID:39001383
Results from the Children's Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma., PMID:37969125
Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma., PMID:37398992
Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma., PMID:37306107
Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer., PMID:36709663
Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group., PMID:36669140
The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models., PMID:36322002
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer., PMID:34642026
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer., PMID:34611148
Efficacy and Safety of Regorafenib in Combination with Chemotherapy as Second-Line Treatment in Patients with Metastatic Colorectal Cancer: A Network Meta-Analysis and Systematic Literature Review., PMID:32770529
A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer., PMID:29572245
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer., PMID:29123263
Flagellate Dermatitis in a Child Most Likely Secondary to Doxorubicin., PMID:28804924
A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer., PMID:28601388
Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy., PMID:28427155
Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials., PMID:28256961
A network meta-analysis on the efficacy of sixteen targeted drugs in combination with chemotherapy for treatment of advanced/metastatic colorectal cancer., PMID:27806321
Recent advances in targeted therapy for Ewing sarcoma., PMID:27635231
Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade., PMID:26429980
Minireview: Were the IGF Signaling Inhibitors All Bad?, PMID:26366975
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial., PMID:25609246
A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells., PMID:25344862
Ganitumab for the treatment of small-cell lung cancer., PMID:25189625
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer., PMID:24919569
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab., PMID:24816908
Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study., PMID:24782485
Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy., PMID:24727326
IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice., PMID:24492468
Differential Pharmacokinetics of Ganitumab in Patients With Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers., PMID:27121941
Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts., PMID:23823800
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor., PMID:23741071
Therapy: Blockade of IGF-1R-not effective in neuroendocrine tumours., PMID:23732282
A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors., PMID:23572164
Anticancer IGF1R classes take more knocks., PMID:23535923
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer., PMID:23510984
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial., PMID:23414585
IGF-1R inhibition: right direction, wrong pathway?, PMID:23414584
Epitope-specific mechanisms of IGF1R inhibition by ganitumab., PMID:23383308
Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts., PMID:23348048
Clinical setbacks reduce IGF-1 inhibitors to cocktail mixers., PMID:23051797
The impact of timing of EGFR and IGF-1R inhibition for sensitizing head and neck cancer to radiation., PMID:22843870
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors., PMID:22810805
Insulin-like growth factor receptor inhibitors: baby or the bathwater?, PMID:22761272
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer., PMID:22700995
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer., PMID:22678353
Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts., PMID:22562985
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors., PMID:22510349
Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors., PMID:22508822
AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways., PMID:21846689
For research use only. Not for human or drug use.
